WallStSmart

Boston Scientific Corp (BSX)vsIRIDEX Corporation (IRIX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 40611% more annual revenue ($21.00B vs $51.57M). BSX leads profitability with a 17.5% profit margin vs -6.9%. BSX appears more attractively valued with a PEG of 0.60. BSX earns a higher WallStSmart Score of 72/100 (B).

BSX

Strong Buy

72

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 6.7Quality: 5.5
Piotroski: 5/9Altman Z: 1.78

IRIX

Avoid

32

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 7.7Quality: 4.5
Piotroski: 4/9Altman Z: -2.51
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXOvervalued (-10.0%)

Margin of Safety

-10.0%

Fair Value

$39.07

Current Price

$42.98

$3.91 premium

UndervaluedFair: $39.07Overvalued
IRIXUndervalued (+74.4%)

Margin of Safety

+74.4%

Fair Value

$5.59

Current Price

$0.66

$4.93 discount

UndervaluedFair: $5.59Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX6 strengths · Avg: 8.2/10
Market CapQuality
$62.29B9/10

Large-cap with strong market position

PEG RatioValuation
0.608/10

Growing faster than its price suggests

P/E RatioValuation
17.5x8/10

Attractively priced relative to earnings

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

Free Cash FlowQuality
$1.28B8/10

Generating 1.3B in free cash flow

IRIX1 strengths · Avg: 8.0/10
PEG RatioValuation
0.948/10

Growing faster than its price suggests

Areas to Watch

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

IRIX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$12.20M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.103/10

Elevated debt levels

Return on EquityProfitability
-126.4%2/10

ROE of -126.4% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.60 suggests the stock is reasonably priced for its growth.

Bull Case : IRIX

The strongest argument for IRIX centers on PEG Ratio. PEG of 0.94 suggests the stock is reasonably priced for its growth.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Bear Case : IRIX

The primary concerns for IRIX are EPS Growth, Market Cap, Debt/Equity.

Key Dynamics to Monitor

BSX profiles as a mature stock while IRIX is a turnaround play — different risk/reward profiles.

IRIX carries more volatility with a beta of 0.64 — expect wider price swings.

BSX is growing revenue faster at 7.5% — sustainability is the question.

BSX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (72/100 vs 32/100), backed by strong 17.5% margins. IRIX offers better value entry with a 74.4% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

IRIDEX Corporation

HEALTHCARE · MEDICAL DEVICES · USA

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat vision-threatening eye diseases in ophthalmology. The company is headquartered in Mountain View, California.

Want to dig deeper into these stocks?